Patent classifications
C07D205/02
HETEROCYCLIC INHIBITORS OF MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:
##STR00001##
Methods of inhibition MCT4 activity in a human or animal subject are also provided.
HETEROCYCLIC INHIBITORS OF MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:
##STR00001##
Methods of inhibition MCT4 activity in a human or animal subject are also provided.
Heterocyclic inhibitors of MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: ##STR00001## Methods of inhibition MCT4 activity in a human or animal subject are also provided.
Heterocyclic inhibitors of MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: ##STR00001## Methods of inhibition MCT4 activity in a human or animal subject are also provided.
PROCESS FOR PREPARING EGFR INHIBITORS
The present disclosure provides methods of producing a compound of structural formula (I): (I) or a pharmaceutically acceptable salt thereof.
##STR00001##
HETEROCYCLIC INHIBITORS OF MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:
##STR00001##
Methods of inhibition MCT4 activity in a human or animal subject are also provided.
HETEROCYCLIC INHIBITORS OF MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:
##STR00001##
Methods of inhibition MCT4 activity in a human or animal subject are also provided.
SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
Process of making adamantanamides
An effective process of making adamantanamide, which process is fast, does not the use of organic solvents or labor-intensive isolation or purification of the product, by removal of organic solvent or by-products, and has improved yield and purity.
Process of making adamantanamides
An effective process of making adamantanamide, which process is fast, does not the use of organic solvents or labor-intensive isolation or purification of the product, by removal of organic solvent or by-products, and has improved yield and purity.